# FDA Inspection 1214536 - AxoGen Corporation - August 04, 2023

Source: https://www.keypedia.com/records/fda_inspections/axogen-corporation/2fc06565-b616-4eb4-b416-e24adeff880b
Source feed: FDA_Inspections

> FDA Inspection 1214536 for AxoGen Corporation on August 04, 2023. Classification: No Action Indicated (NAI).

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1214536
- Company Name: AxoGen Corporation
- Inspection Date: 2023-08-04
- Classification: No Action Indicated (NAI)
- Project Area: Blood and Blood Products
- Product Type: Biologics
- Office Name: Center for Biologics Evaluation and Research

## Related Documents

- [FDA Inspection 1214536 - 2023-08-04](https://www.keypedia.com/records/fda_inspections/axogen-corporation/55e2493e-6920-4742-ba42-198d2247e1bc)
- [FDA Inspection 1040447 - 2018-02-08](https://www.keypedia.com/records/fda_inspections/axogen-corporation/76a73d00-71a5-4ef7-be89-665fff16aa4d)
- [FDA Inspection 1040447 - 2018-02-08](https://www.keypedia.com/records/fda_inspections/axogen-corporation/1bf2936a-63aa-4edd-a1b4-a70411db7942)

Company: https://www.keypedia.com/companies/axogen-corporation/a43af3b1-a05c-440e-930c-a685952a6d70

Office: https://www.keypedia.com/offices/center-for-biologics-evaluation-and-research/dd9e8ea7-6f04-4ed1-b0d7-e7e6b264570d